Charles River partners with Medigen Vaccine Biologics on NGS-backed multivalent enterovirus vaccine development
CRL•Collaboration on next-generation enterovirus vaccine development
Charles River entered a collaboration with Medigen Vaccine Biologics to support development of a next-generation multivalent enterovirus vaccine.
- Charles River will use next-generation sequencing to characterize and validate Medigen’s virus seed bank, supporting CMC work.
- The partnership targets faster development timelines, stronger regulatory readiness, and support for IND-enabling non-clinical studies.
- The companies also plan to assess further joint work across other vaccine programs.
